In 2011, the Pharmasyntez Group of Companies started the construction in Saint Petersburg of the plant for the development and production of up-to-date and efficient cytostatic pharmaceuticals.

The plant’s first stage started up in 2017. V.V. Putin, President of the Russian Federation inaugurated the plant’s second stage in the spring 2023. The third stage of the plant's development is currently under way, and an investment agreement has been signed to begin work on the construction of the plant’s fourth stage.

The project was integrated into the state import substitution program.

Today, Pharmasyntez-Nord JSC is a contemporary, top-tier pharmaceutical research and production complex with a focus on the development and production of biotechnology drugs and the drugs for the treatment of oncology, autoimmune diseases, and diabetes mellitus.  Pharmasyntez-Nord JSC now produces 45 trade names of antineoplastic drugs, and 99% of them are included in the List of Vital and Essential Drugs of the Russian Ministry of Health. In September 2023, the company started the production of the first recombinant long-acting human insulin analog.

Mikhail Yuryevich Kvasnikov

Chief Executive Officer of Pharmasyntez-Nord, JSC

• Fully automatic line for the manufacturing of aseptic and lyophilized products with the fill-finish technology applied
• Robotized isolated line for filling vials, cartridges, and pre-filled syringes (PFS) with the fill-finish technology applied
• Isolated line for coated tablets, capsules, and pellet manufacturing by Cos. Mec and B&D (Italy)